MANAGEMENT OF SUPERFICIAL THROMBOPHLEBITIS

浅表血栓静脉炎的治疗

• 批准号: 7608092
• 负责人: SUMAN W RATHBUN
• 金额: $ 1.46万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608092
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Daily; Dalteparin; Dalteparin Sodium; Data; Funding; Grant; Hemorrhage; Ibuprofen; Incidence; Institution; Low-Molecular-Weight Heparin; Oral; Pain; Patients; Pharmaceutical Economics; Pharmaceutical Preparations; Research; Research Personnel; Resolution; Resources; Risk; Source; Testing; Thrombophlebitis; Time; Ultrasonography; United States National Institutes of Health; day; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: Test the hypothesis that Fragmin (dalteparin sodium) 200 units/kg subcutaneously given at the time of presentation followed by 10,000 units given subcutaneously once daily for 6 days is more effective that Ibuprofen 800mg given orally three times daily for 7 days for the treatment of superficial thrombophlebitis. Specific Aims1. To evaluate the incidence of extension of superficial thrombophlebitis by ultrasound imaging in patients treated with dalteparin 200 units/kg at presentation followed by 10,000 units subcutaneously (sc) once daily or Ibuprofen 800mg orally three times daily.2. To evaluate the degree of pain resolution while taking the prescribed medication.3. To evaluate the risk of bleeding associated with the treatments.4. To gather descriptive/demographic data on patients with superficial thrombophlebitis.5. To perform a pharmacoeconomic assessment of treatment of superficial thrombophlebitis using low molecular weight heparin (Fragmin) versus oral ibuprofen.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：检验以下假设：对于浅表血栓性静脉炎的治疗，在就诊时皮下给予法安明（达肝素钠）200单位/kg，随后皮下给予10，000单位，每日一次，持续6天，比口服给予Istatin 800 mg，每日三次，持续7天更有效。 具体目标1。 通过超声成像评价在接受达肝素200单位/kg治疗的患者中血栓性浅静脉炎扩展的发生率，随后接受10，000单位皮下（sc）每日一次或Ithrin 800 mg口服每日三次。 评估服用处方药物时疼痛缓解的程度. 评估与治疗相关的出血风险. 收集血栓性浅静脉炎患者的描述性/人口统计学数据。 对使用低分子量肝素（法安明）与口服布洛芬治疗血栓性浅静脉炎进行药物经济学评估。